A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration

Launched by PEKING UNIVERSITY THIRD HOSPITAL · Aug 19, 2024

Keywords

ClinConnect Summary

This clinical trial is looking into hereditary ovarian cancer, specifically focusing on understanding the genetic factors that contribute to this condition. Researchers aim to create a model that can predict the risk of ovarian cancer for women in families with a history of the disease. By analyzing medical records, genetic test results, and family histories, the study hopes to provide valuable information that can help identify other family members who might be at higher risk and guide their healthcare management.

To participate in this study, women aged 18 and older who have been diagnosed with epithelial ovarian cancer and have a confirmed genetic mutation related to cancer are eligible. Unfortunately, women with non-epithelial ovarian cancer or without a genetic test cannot join. Participants can expect to undergo genetic testing and contribute to a better understanding of ovarian cancer, which may help improve risk prediction and treatment options for future patients. This study is currently recruiting participants, so if you or someone you know meets the criteria, it could be a meaningful opportunity to contribute to important research.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Epithelial ovarian cancer
• • ≥18 years
• • The pathological diagnosis was clear
• • The genetic test showed germ line pathogenic/suspected pathogenic mutations (for mutation interpretation, refer to the American ACMG Classification Standards and Guidelines for Genetic Variation)
• Exclusion Criteria:
• • Non-epithelial ovarian cancer was confirmed by pathology
• • No genetic test has been performed